Discover undervalued stocks with Eulerpool.

Subscribe for $2

10X Genomics Stock TXG

Price

12.32
Today +/-
-0.04
Today %
-0.40 %

10X Genomics stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the 10X Genomics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the 10X Genomics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the 10X Genomics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze 10X Genomics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

10X Genomics Stock Price History

Date10X Genomics Price
10/2/202512.32 undefined
10/1/202512.37 undefined
9/30/202511.70 undefined
9/28/202511.34 undefined
9/25/202511.72 undefined
9/24/202511.95 undefined
9/24/202512.10 undefined
9/23/202512.61 undefined
9/22/202513.18 undefined
9/19/202513.05 undefined
9/18/202513.35 undefined
9/17/202512.87 undefined
9/16/202513.13 undefined
9/15/202513.09 undefined
9/12/202512.65 undefined
9/11/202512.81 undefined
9/10/202512.65 undefined
9/9/202513.61 undefined
9/8/202513.96 undefined
9/5/202514.01 undefined
9/4/202513.85 undefined
9/3/202513.27 undefined

10X Genomics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into 10X Genomics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by 10X Genomics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects 10X Genomics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of 10X Genomics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into 10X Genomics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing 10X Genomics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on 10X Genomics’s growth potential.

10X Genomics Revenue, EBIT and net profit per share

Date10X Genomics Revenue10X Genomics EBIT10X Genomics Net Income
2030e861.53 M undefined0 undefined41.36 M undefined
2029e741.74 M undefined-121.84 M undefined14.6 M undefined
2028e724.29 M undefined-86.09 M undefined-12.17 M undefined
2027e681.79 M undefined-80.24 M undefined-76.61 M undefined
2026e614.48 M undefined-130.19 M undefined-115.57 M undefined
2025e623.93 M undefined-81.72 M undefined-72.74 M undefined
2024610.79 M undefined-192.46 M undefined-182.63 M undefined
2023618.73 M undefined-194.95 M undefined-255.1 M undefined
2022516.4 M undefined-167.9 M undefined-166 M undefined
2021490.5 M undefined-52.3 M undefined-58.2 M undefined
2020298.8 M undefined-531.6 M undefined-542.7 M undefined
2019245.9 M undefined-30.6 M undefined-31.3 M undefined
2018146.3 M undefined-110.8 M undefined-112.5 M undefined
201771.1 M undefined-18.4 M undefined-18.8 M undefined

10X Genomics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201720182019202020212022202320242025e2026e2027e2028e2029e2030e
71146245298490516618610623614681724741861
-105.6367.8121.6364.435.3119.77-1.292.13-1.4410.916.312.3516.19
84.5180.1475.1080.5484.9076.7466.1867.8766.4567.4360.7957.1855.8748.08
60117184240416396409414000000
-18-112-31-542-58-166-255-182-72-115-76-121441
-522.22-72.321,648.39-89.30186.2153.61-28.63-60.4459.72-33.91-84.21-216.67192.86
93.893.896.2101.2110.3113.9117.17120.45000000
- - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The 10X Genomics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the 10X Genomics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (B)
20172018201920202021202220232024
               
47.965.1424.2663.6587.4430388.7393.4
13.328.133.451.285.3104.2114.8387.86
01.5000000
4.88.615.3306081.673.7183.11
2.13829.614.919.218.7920.02
68.1106.3480.9774.4747.6635596.02584.39
6.911.148.8119.8230.4359.2344.93309.94
00000000
00000000
00022.425.422.916.6215.67
00004.54.54.514.51
0.66.976.312.810.97.43.064.13
7.518125.1155271.2394369.12334.25
0.080.120.610.931.021.030.970.92
               
158.4243.2000000
0.010.010.681.541.681.842.032.18
-118.6-231.1-262.4-805.1-863.3-1,029.3-1,284.42-1,467.05
000-0.10-4.3-0.43-0.49
00000000
45.923.3420.1739817.6805.8741.04710.13
5.48.8134.717.421.615.7412.91
912.13092.375.887.780.762
3.57.310.121.117.221.730.7342.72
00000000
4.24.29.900000
22.132.463118.1110.4131127.16117.63
6.325.519.800000
00000000
1.243.210372.190.992.396.9490.87
7.568.7122.872.190.992.396.9490.87
29.6101.1185.8190.2201.3223.3224.1208.5
0.080.120.610.931.021.030.970.92
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of 10X Genomics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand 10X Genomics's financial health and stability.

Assets

10X Genomics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that 10X Genomics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of 10X Genomics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into 10X Genomics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-18-112-31-542-58-166-255
43714212535
0000000
12844-50-87-3917
3627409199283353
0121100
0000834
-10-7634-217-21-33-15
-3-6-42-38-101-131-49
-3-6-42-38-106-350133
0000-5-219183
0000000
0180-31000
2086414506402119
20105414468351513
----5.00-5.00-5.00-5.00
0000000
622406212-92-368131
-14.46-83.12-8.14-256.29-122.65-165.27-64.72
0000000

10X Genomics stock margins

The 10X Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of 10X Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for 10X Genomics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the 10X Genomics's sales revenue. A higher gross margin percentage indicates that the 10X Genomics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the 10X Genomics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the 10X Genomics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the 10X Genomics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the 10X Genomics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the 10X Genomics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

10X Genomics Margin History

10X Genomics Gross margin10X Genomics Profit margin10X Genomics EBIT margin10X Genomics Profit margin
2030e67.91 %0 %4.8 %
2029e67.91 %-16.43 %1.97 %
2028e67.91 %-11.89 %-1.68 %
2027e67.91 %-11.77 %-11.24 %
2026e67.91 %-21.19 %-18.81 %
2025e67.91 %-13.1 %-11.66 %
202467.91 %-31.51 %-29.9 %
202366.15 %-31.51 %-41.23 %
202276.68 %-32.51 %-32.15 %
202184.89 %-10.66 %-11.87 %
202080.46 %-177.91 %-181.63 %
201975.19 %-12.44 %-12.73 %
201880.45 %-75.73 %-76.9 %
201785.09 %-25.88 %-26.44 %

10X Genomics Stock Sales Revenue, EBIT, Earnings per Share

The 10X Genomics earnings per share therefore indicates how much revenue 10X Genomics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue 10X Genomics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates 10X Genomics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of 10X Genomics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating 10X Genomics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

10X Genomics Revenue, EBIT and net profit per share

Date10X Genomics Sales per Share10X Genomics EBIT per share10X Genomics Earnings per Share
2030e7.15 undefined0 undefined0.34 undefined
2029e6.16 undefined0 undefined0.12 undefined
2028e6.01 undefined0 undefined-0.1 undefined
2027e5.66 undefined0 undefined-0.64 undefined
2026e5.1 undefined0 undefined-0.96 undefined
2025e5.18 undefined0 undefined-0.6 undefined
20245.07 undefined-1.6 undefined-1.52 undefined
20235.28 undefined-1.66 undefined-2.18 undefined
20224.53 undefined-1.47 undefined-1.46 undefined
20214.45 undefined-0.47 undefined-0.53 undefined
20202.95 undefined-5.25 undefined-5.36 undefined
20192.56 undefined-0.32 undefined-0.33 undefined
20181.56 undefined-1.18 undefined-1.2 undefined
20170.76 undefined-0.2 undefined-0.2 undefined

10X Genomics business model

10X Genomics is a US-based company specializing in the development of life science products. It was founded in 2012 by Serge Saxonov and Ben Hindson and is headquartered in Pleasanton, California. The company's business model focuses on providing technology platforms that enable researchers and scientists to analyze and understand complex biological data. It combines microfluidics, genomics, and bioinformatics. 10X Genomics is divided into different divisions, each focusing on different products and applications: Single-Cell Genomics, Long-Read Sequencing, Immune Profiling, and Spatial Transcriptomics. The company's products include the Chromium platform for cell type identification, disease research, and drug screening; Long-Read Sequencing technology for reading larger DNA fragments; tools and solutions for immune profiling and understanding the immune system; and Spatial Transcriptomics technology for studying the spatial organization of gene expression in tissues. 10X Genomics also offers other products and solutions in the field of genomic sequencing and analysis, including DNA preparation and sequencing kits, software for DNA data analysis and interpretation, and consulting and training services. The company has received various awards and recognition for its innovative approach, including the Innovation Award from The Scientist magazine and the Disruptive Technology Award from the Wall Street Journal. Overall, 10X Genomics has become a leading company in the life science industry, contributing to the advancement of scientific understanding and supporting progress in medicine and biotechnology. 10X Genomics is one of the most popular companies on Eulerpool.com.

10X Genomics SWOT Analysis

Strengths

1. Technological Innovation: 10X Genomics Inc is known for its cutting-edge technology in single-cell genomics. Their innovative solutions enable researchers to gain unprecedented insights into complex biological systems.

2. Broad Product Portfolio: The company offers a wide range of products and solutions, including instruments, consumables, and software, catering to various research needs in genomics and transcriptomics.

3. Strong Customer Base: 10X Genomics has established a strong customer base globally, including leading academic institutions and pharmaceutical companies, with high customer satisfaction and loyalty.

4. Strategic Partnerships: The company has forged strategic partnerships with key players in the genomics industry, enhancing its market presence, expanding distribution networks, and fostering collaborations.

Weaknesses

1. High Pricing: The advanced technologies offered by 10X Genomics come at a premium price, limiting accessibility for smaller research institutions or budget-constrained customers.

2. Dependence on Research Funding: The company's revenue is significantly dependent on research grants and funding, which are subject to fluctuations and uncertainties, impacting financial stability.

3. Limited Global Market Penetration: While the company has established a strong presence in certain regions, its market penetration in other geographical areas may be relatively low, indicating room for further growth.

Opportunities

1. Increasing Demand for Genomic Research: The growing interest in personalized medicine and the need for understanding complex diseases present tremendous opportunities for 10X Genomics to expand its customer base and market share.

2. Mergers & Acquisitions: The company can explore strategic acquisitions or partnerships to enhance its product offerings, access new technologies, and strengthen its competitive position in the genomics market.

3. Expansion into Emerging Markets: 10X Genomics can focus on expanding its operations into emerging markets where the adoption of genomics research is on the rise, opening up new revenue streams.

Threats

1. Intense Competition: The genomics industry is highly competitive, with several established players and new entrants competing for market share, posing a threat to 10X Genomics' growth and profitability.

2. Regulatory Challenges: Evolving regulations and compliance requirements in the genomics sector could increase operational complexities and costs for 10X Genomics, limiting its ability to address certain markets.

3. Technological Advancements by Competitors: The rapid pace of technological advancements by competitors may pose a threat to 10X Genomics' market position if it fails to innovate and stay at the forefront of new developments.

10X Genomics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

10X Genomics Revenue by Segment

Segmente20232022202120202019
Consumables479.55 M USD435.59 M USD418.74 M USD252.69 M USD206.88 M USD
Instruments123.47 M USD72.4 M USD64.47 M USD40.13 M USD-
Services15.7 M USD8.43 M USD7.28 M USD6.03 M USD-
Instuments----34.95 M USD
Service----4.07 M USD

10X Genomics Revenue by Region

  • 3 years

  • 5 years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

10X Genomics Revenue by Segment

DateAmericasAsia PacificAsia-PacificAsia-Pacific (excluding China)ChinaCHINAEMEAEurope, Middle East and AfricaNorth AmericaNorth America (excluding United States)United States
2023373.19 M USD-103.26 M USD----142.28 M USD---
2022---46 M USD59.56 M USD--117.07 M USD-8.79 M USD284.99 M USD
2021---42.09 M USD74.92 M USD--108.49 M USD-6.71 M USD258.27 M USD
2020--24.51 M USD-41.74 M USD--73.27 M USD159.33 M USD--
2019-18.21 M USD---29.92 M USD58 M USD-139.76 M USD--
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

10X Genomics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

10X Genomics historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

10X Genomics shares outstanding

The number of shares was 10X Genomics in 2024 — This indicates how many shares 120.452 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue 10X Genomics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates 10X Genomics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of 10X Genomics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating 10X Genomics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for 10X Genomics.

10X Genomics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.38 0.28  (174.61 %)2025 Q2
3/31/2025-0.48 -0.36  (24.35 %)2025 Q1
12/31/2024-0.3 -0.4  (-34.41 %)2024 Q4
9/30/2024-0.35 -0.3  (13.04 %)2024 Q3
6/30/2024-0.48 -0.32  (33.83 %)2024 Q2
3/31/2024-0.51 -0.5  (1.07 %)2024 Q1
12/31/2023-0.36 -0.41  (-13.26 %)2023 Q4
9/30/2023-0.46 -0.79  (-70.22 %)2023 Q3
6/30/2023-0.41 -0.53  (-30 %)2023 Q2
3/31/2023-0.38 -0.44  (-16.53 %)2023 Q1
1
2
3

Eulerpool ESG Scorecard© for the 10X Genomics stock

Eulerpool World ESG Rating (EESG©)

28/ 100

🌱 Environment

32

👫 Social

19

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

10X Genomics shareholders

%
Name
Stocks
Change
Date
11.53335 % ARK Investment Management LLC13,892,1031,046,3906/30/2025
10.30804 % The Vanguard Group, Inc.12,416,1981,321,9746/30/2025
6.34662 % Fidelity Management & Research Company LLC7,644,611-930,7846/30/2025
6.29415 % BlackRock Institutional Trust Company, N.A.7,581,4052,173,0506/30/2025
4.99617 % Sumitomo Mitsui Trust Bank, Limited6,017,963654,5976/30/2025
3.43524 % AQR Capital Management, LLC4,137,8012,925,3726/30/2025
2.41289 % BofA Global Research (US)2,906,359350,9936/30/2025
2.39418 % Millennium Management LLC2,883,827-2,649,7916/30/2025
2.35809 % Two Sigma Investments, LP2,840,361-329,6446/30/2025
2.20073 % Geode Capital Management, L.L.C.2,650,819773,2036/30/2025
1
2
3
4
5
...
10

10X Genomics Executives and Management Board

Mr. Serge Saxonov

(47)
10X Genomics Chief Executive Officer, Co-Founder, Director (since 2012)
Compensation 8.29 M

Dr. Benjamin Hindson

(49)
10X Genomics President, Co-Founder, Chief Scientific Officer, Director (since 2012)
Compensation 4.43 M

Mr. Eric Whitaker

(57)
10X Genomics Chief Legal Officer
Compensation 3.88 M

Dr. John Stuelpnagel

(66)
10X Genomics Independent Chairman of the Board
Compensation 403,585

Mr. Sridhar Kosaraju

(46)
10X Genomics Independent Director
Compensation 346,389
1
2
3

Most common questions regarding 10X Genomics

What values and corporate philosophy does 10X Genomics represent?

10X Genomics Inc represents a commitment to advancing scientific research and discovery. Their corporate philosophy emphasizes innovation, collaboration, and integrity. The company aims to empower researchers with cutting-edge tools and technologies to unlock new insights in genomics. By offering solutions that enable single-cell and spatial genomics analysis, 10X Genomics Inc plays a vital role in accelerating knowledge in biology and medicine. Their dedication to quality and customer satisfaction has established them as a leader in the field, making 10X Genomics Inc a trusted name in genomics research and a driving force for scientific progress.

In which countries and regions is 10X Genomics primarily present?

10X Genomics Inc is primarily present in the United States.

What significant milestones has the company 10X Genomics achieved?

10X Genomics Inc has achieved several significant milestones in its development. The company successfully launched its groundbreaking Chromium System, a single-cell analysis platform that enables researchers to analyze cellular heterogeneity at unprecedented resolution. This technological breakthrough has revolutionized genomics research and allowed scientists to gain invaluable insights into complex biological systems. Additionally, 10X Genomics Inc has made remarkable strides in expanding its product portfolio, continuously introducing innovative solutions that empower researchers with cutting-edge genomic tools. Furthermore, the company has established strong partnerships and collaborations with leading academic institutions and pharmaceutical companies, further validating 10X Genomics Inc's expertise and impact in the genomics field.

What is the history and background of the company 10X Genomics?

10X Genomics Inc is a biotechnology company headquartered in Pleasanton, California. It was founded in 2012 by Serge Saxonov, Benjamin Hindson, and Kevin Ness with a vision to revolutionize genomics research. The company develops and commercializes innovative solutions that enable scientists to study genetic information at unprecedented resolution and scale. By employing its patented technology, 10X Genomics has empowered researchers across multiple disciplines to make groundbreaking discoveries in areas such as cancer research, drug discovery, and immunology. With a strong focus on innovation, 10X Genomics continues to shape the future of genomics research, ensuring its position as a leading player in the field.

Who are the main competitors of 10X Genomics in the market?

The main competitors of 10X Genomics Inc in the market include other innovative biotechnology companies such as Illumina, Pacific Biosciences, and Bio-Rad Laboratories.

In which industries is 10X Genomics primarily active?

10X Genomics Inc is primarily active in the life sciences industry.

What is the business model of 10X Genomics?

The business model of 10X Genomics Inc is focused on providing innovative solutions for single-cell genomics analysis. They develop and manufacture advanced instruments, software, and reagents that enable researchers to profile individual cells at high resolution. By offering comprehensive tools for single-cell analysis, 10X Genomics aims to revolutionize how scientists understand cellular diversity, gene expression, and the mechanisms underlying diseases. Through their state-of-the-art technologies, 10X Genomics empowers researchers across various disciplines to gain valuable insights into complex biological systems and ultimately accelerate discoveries in genomics research.

What is the P/E ratio of 10X Genomics 2025?

The 10X Genomics P/E ratio is -20.4.

What is the P/S ratio of 10X Genomics 2025?

The 10X Genomics P/S ratio is 2.38.

What is the Quality Investing of 10X Genomics?

The Quality Investing for 10X Genomics is 3/10.

What is the revenue of 10X Genomics 2025?

The expected 10X Genomics revenue is 623.93 M USD.

How high is the profit of 10X Genomics 2025?

The expected 10X Genomics profit is -72.74 M USD.

What is the business model of 10X Genomics

The company 10X Genomics Inc. is a leading provider of genomics technologies and solutions. Its business model is focused on providing innovative tools and products to scientists, researchers, and other customers to improve the understanding of cell biology and genomics. 10X Genomics' main division is the production of single-cell genomics products. The company has developed a unique platform that allows researchers to study individual cells and collect genetic information from them. This platform offers higher resolution than previous technologies that relied on samples from multiple cells, which obscured the misunderstood heterogeneity of cell populations. Numerous differences occurring in cells can be uncovered, allowing scientists to gain new insights into biological processes. 10X Genomics also offers solutions for genome sequencing and has developed a revolutionary technology called Linked-Reads. With this technology, researchers can sequence regions of the genome that were previously inaccessible, leading to important discoveries. Linking specific regions in the DNA helps researchers study large genomic areas more quickly and identify complex structures such as chromosomal variations or gene fusion events. Additionally, 10X Genomics has a growing presence in the market for clinical applications of genomics technologies. The company is currently collaborating with several partners to develop tests and diagnostic tools for early cancer detection, among other future uses. 10X Genomics' business model is based on the development and manufacture of innovative products and technologies, as well as collaboration with customers to create tailored solutions and sell them with added value. The company has experienced rapid growth in the past and values continuous improvement and development of its products and services. In the future, 10X Genomics plans to continue working on new technologies and solutions while expanding and strengthening its existing customer base by closely collaborating with customers in research and clinical diagnostics. The company is demonstrating to the industry how analyzing individual cells in genomics can enable scientists to explore biological complexity in new, deeper ways.

What is the 10X Genomics dividend?

10X Genomics pays a dividend of 0 USD distributed over payouts per year.

How often does 10X Genomics pay dividends?

The dividend cannot currently be calculated for 10X Genomics or the company does not pay out a dividend.

What is the 10X Genomics ISIN?

The ISIN of 10X Genomics is US88025U1097.

What is the 10X Genomics WKN?

The WKN of 10X Genomics is A2PPQJ.

What is the 10X Genomics ticker?

The ticker of 10X Genomics is TXG.

How much dividend does 10X Genomics pay?

Over the past 12 months, 10X Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 10X Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of 10X Genomics?

The current dividend yield of 10X Genomics is .

When does 10X Genomics pay dividends?

10X Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of 10X Genomics?

10X Genomics paid dividends every year for the past 0 years.

What is the dividend of 10X Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is 10X Genomics located?

10X Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von 10X Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of 10X Genomics from 10/3/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2025.

When did 10X Genomics pay the last dividend?

The last dividend was paid out on 10/3/2025.

What was the dividend of 10X Genomics in the year 2024?

In the year 2024, 10X Genomics distributed 0 USD as dividends.

In which currency does 10X Genomics pay out the dividend?

The dividends of 10X Genomics are distributed in USD.

All fundamentals about 10X Genomics

Our stock analysis for 10X Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 10X Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.